2020
DOI: 10.1101/2020.09.11.291534
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

A non-canonical EZH2 function sensitizes solid tumors to genotoxic stress

Abstract: SummaryDrugs that block the activity of the methyltransferase EZH2 are in clinical development for the treatment of non-Hodgkin lymphomas harboring gain-of-function EZH2 mutations that enhance its polycomb repressive function. In contrast, in castration-resistant prostate cancer (CRPC) we have previously reported that EZH2 plays a non-canonical role as a transcriptional activator. In this setting, we now show that EZH2 inhibitors can also block the non-canonical activity of EZH2 and inhibit the growth of CRPC … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

2
0
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 60 publications
2
0
0
Order By: Relevance
“…Taken together, these results significantly extend previous knowledge on non-immuno-related anti-tumor activities of epigenetic inhibitors, such as reactivation of tumor suppressor genes by demethylating agents [47], promotion of cell death and suppression of angiogenesis by HDAC inhibitors [48], inhibition of proto-oncogenes MYC and BCL2 by BET inhibitors [49] and downregulation of DNA repair genes by EZH2 inhibitors [50].…”
Section: Discussionsupporting
confidence: 83%
See 1 more Smart Citation
“…Taken together, these results significantly extend previous knowledge on non-immuno-related anti-tumor activities of epigenetic inhibitors, such as reactivation of tumor suppressor genes by demethylating agents [47], promotion of cell death and suppression of angiogenesis by HDAC inhibitors [48], inhibition of proto-oncogenes MYC and BCL2 by BET inhibitors [49] and downregulation of DNA repair genes by EZH2 inhibitors [50].…”
Section: Discussionsupporting
confidence: 83%
“…The drugs affected also expression of genes encoding proteolytic enzymes (cathepsins), and their inhibitors (serpins), thus implicating epigenetic drugs in the regulation of different cancer-related processes, controlled by cathepsins, such as proliferation, angiogenesis, metastasis and invasion. Taken together, these results significantly extend previous knowledge on non-immuno-related anti-tumor activities of epigenetic inhibitors, such as reactivation of tumor suppressor genes by demethylating agents [47], promotion of cell death and suppression of angiogenesis by HDAC inhibitors [48], inhibition of proto-oncogenes MYC and BCL2 by BET inhibitors [49] and downregulation of DNA repair genes by EZH2 inhibitors [50].…”
Section: Discussionsupporting
confidence: 82%